Tevogen Inc. (TVGN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, TVGN scores 40 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 8/20 (ROIC of -35%; FCF yield of -13.02%); Whale 13F Flow scores 7/20 (institutional accumulation and options positioning); Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 12/20 (Beta of 1.0; sector sensitivity); and Forensic Balance Sheet scores 10/20 (Altman Z of 2.5; Piotroski F of 1/9; Debt/Equity of 0.5).

For a prospective investor, the weakest pillars are cash generation and insider conviction. Negative ROIC and negative FCF yield indicate the company is not currently converting capital into cash returns, so any valuation case must rest on future outcomes rather than current earnings power. The low insider conviction score signals limited insider-side confirmation of the thesis. The Piotroski F-Score of 1/9 points to weak fundamental health signals, while the Altman Z of 2.5 sits in the range the rating frames as less distressed than deeply distressed, but not comfortably healthy. Upside drivers would need to come from a catalyst that changes the cash profile; the news wire currently shows a pending letter of intent to evaluate an acquisition, which is an evaluation step rather than a completed transaction. Valuation tradeoffs are significant: the market cap of $95.2M against zero reported revenue and negative operating income means the price reflects expectations not visible in the reported financials.

Per the SEC financials, the company reported no revenue and negative operating and net income across the three periods, with gross, operating, and net margins each shown as 0% in the market data. Per the market data, ROIC is -35% and FCF yield is -13.02%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Cash is reported as $0.0M for FY 2025 and FY 2024, and debt is listed as N/A in all periods.

Per the recent news and catalysts feed, the most substantive items concern a letter of intent to evaluate a potential acquisition of HRK Healthcare, appearing in a Yahoo Finance headline and an updated version of that headline. Other items are secondary market-commentary pieces from TradingView, Yahoo Finance UK, and two aggregator sources reporting a 0.87% decline to $6.82 and noting shares testing the lower end of a recent range. All items are flagged YELLOW. The feed does not disclose terms, timing, or financing for the proposed transaction. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

• What are the terms, financing structure, and expected timing of the proposed evaluation of the HRK Healthcare acquisition?
• What products or programs generate or are expected to generate revenue, given zero reported revenue across the listed periods?
• What is the company's cash position and debt structure, since cash and debt are reported as $0.0M or N/A in the financials?
• What explains the swing in FY 2023 and FY 2024 operating income versus net income, which diverge materially in the reported figures?
• What are the P/E, EPS, and EV/EBITDA metrics, which are unavailable in the source data?